Hologic, Inc. $HOLX Shares Bought by Capital Fund Management S.A.

Capital Fund Management S.A. raised its position in Hologic, Inc. (NASDAQ:HOLX) by 92.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 305,176 shares of the medical equipment provider’s stock after purchasing an additional 146,800 shares during the quarter. Capital Fund Management S.A.’s holdings in Hologic were worth $18,851,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Victory Capital Management Inc. lifted its holdings in shares of Hologic by 34.4% in the 1st quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider’s stock worth $408,283,000 after acquiring an additional 1,692,177 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of Hologic by 18.8% in the 1st quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider’s stock worth $298,655,000 after acquiring an additional 764,573 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of Hologic by 1.6% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,473,098 shares of the medical equipment provider’s stock worth $276,303,000 after acquiring an additional 69,878 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of Hologic by 26.9% in the 4th quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider’s stock worth $226,898,000 after acquiring an additional 668,086 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Hologic by 8.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,838,656 shares of the medical equipment provider’s stock worth $175,331,000 after acquiring an additional 213,366 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Price Performance

Shares of HOLX opened at $68.76 on Thursday. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.39. The firm’s 50 day moving average price is $65.79 and its 200 day moving average price is $62.55. The company has a market cap of $15.29 billion, a P/E ratio of 28.53, a PEG ratio of 2.46 and a beta of 0.49. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the prior year, the firm earned $1.06 EPS. The firm’s revenue for the quarter was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Morgan Stanley upped their price objective on shares of Hologic from $65.00 to $69.00 and gave the stock an “equal weight” rating in a report on Thursday, July 31st. Raymond James Financial restated an “outperform” rating and issued a $71.00 price objective (down from $90.00) on shares of Hologic in a report on Friday, May 2nd. Royal Bank Of Canada upgraded shares of Hologic from a “sector perform” rating to an “outperform” rating and upped their price objective for the stock from $72.00 to $87.00 in a report on Wednesday, August 6th. Mizuho set a $75.00 price objective on shares of Hologic in a report on Thursday, July 31st. Finally, Argus raised shares of Hologic from a “hold” rating to a “buy” rating and set a $80.00 target price on the stock in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $78.00.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.